Clinical Trial Outcomes Uncertainty: CERO's drug candidates must successfully complete extensive and costly preclinical and clinical trials. There is a high risk that these trials will not demonstrate the necessary safety or efficacy to support regulatory approval, leading to significant delays or the complete cessation of development.

Regulatory Approval Barriers: Obtaining regulatory approvals for new drug products is a complex, uncertain, and lengthy process. CERO may fail to obtain necessary approvals from the FDA or other foreign regulatory agencies, or approvals may be granted with restrictions that limit commercial potential.

Future Capital Requirements: CERO has accumulated significant losses and expects to incur substantial expenses for the foreseeable future as it advances its drug candidates. The company will require additional financing to fund its operations and there is no guarantee that such financing will be available on acceptable terms, or at all.